1. In a patient with alcoholic hepatitis (AH: an acute inflammatory liver injury occurring on a background of heavy alcohol use), which Maddrey discriminant function (DF: a prognostic score calculated from prothrombin time and serum bilirubin) value is the conventional threshold that defines severe disease and identifies candidates for corticosteroid therapy?
A) A DF of 12 or greater
B) A DF of 32 or greater
C) A DF of 50 or greater
D) A DF of 5 or greater
E) A DF of 100 or greater
ANSWER: B
Rationale:
A Maddrey discriminant function of 32 or greater defines severe alcoholic hepatitis, identifying patients with an untreated 28-day mortality of roughly 35 to 45 percent who may derive a survival benefit from corticosteroids; this threshold is the standard entry criterion for steroid therapy.
Option A: Option A is incorrect because a DF of 12 falls well below the severity threshold and would not identify the high-mortality subset for whom steroids are indicated.
Option C: Option C is incorrect because, although a DF of 50 does represent severe disease, 32 (not 50) is the established cutoff; setting the bar at 50 would wrongly exclude eligible patients.
Option D: Option D is incorrect because a DF of 5 indicates mild disease with low short-term mortality and no steroid indication.
Option E: Option E is incorrect because a DF of 100, while reflecting extremely severe disease, is far above the validated 32 threshold and misstates the entry criterion.
2. A patient with severe alcoholic hepatitis has completed 7 days of prednisolone. The Lille model (a score calculated at day 7 to predict response to corticosteroids) returns a value of 0.50. What does this result indicate, and what is the appropriate action?
A) Complete response; continue prednisolone for the full 28 days
B) Partial response; increase the prednisolone dose
C) Complete response; switch to intravenous methylprednisolone
D) Non-response; discontinue prednisolone
E) Non-response; extend prednisolone to 56 days
ANSWER: D
Rationale:
A Lille score of 0.45 or greater at day 7 defines non-response and predicts a 6-month mortality near 75 percent; because these patients gain no survival benefit from continued steroids while accruing infection risk, prednisolone should be discontinued.
Option A: Option A is incorrect because complete response is defined by a Lille score below 0.16, not 0.50, and a score of 0.50 is the opposite of a complete response.
Option B: Option B is incorrect because no Lille category calls for dose escalation; the model guides continuation versus discontinuation, not titration upward, and increasing immunosuppression in a non-responder raises infection risk without benefit.
Option C: Option C is incorrect because the result does not represent a complete response, and switching steroid formulation does not address non-response; oral prednisolone is in fact the preferred formulation.
Option E: Option E is incorrect because extending therapy in a non-responder prolongs immunosuppression with no survival benefit and is not part of the Lille-based algorithm.
3. Which statement best reflects the current role of pentoxifylline (a non-selective phosphodiesterase inhibitor once proposed for alcoholic hepatitis) following the STOPAH trial?
A) It is no longer recommended, because it did not reduce mortality in alcoholic hepatitis
B) It is now first-line therapy, having replaced corticosteroids
C) It is preferred over corticosteroids specifically to prevent hepatorenal syndrome
D) It should be combined with prednisolone in all patients for additive mortality benefit
E) It is the agent of choice when corticosteroids are contraindicated by infection
ANSWER: A
Rationale:
The STOPAH trial showed that prednisolone reduced 28-day mortality whereas pentoxifylline had no significant effect on 28-day, 90-day, or 1-year mortality; current EASL and AASLD guidance therefore does not recommend pentoxifylline, and its clinical use should be abandoned.
Option B: Option B is incorrect because pentoxifylline did not outperform or replace corticosteroids; steroids remain the only pharmacological agent with a demonstrated mortality benefit.
Option C: Option C is incorrect because pentoxifylline failed to reduce hepatorenal syndrome incidence, which had been its principal claimed advantage.
Option D: Option D is incorrect because there is no demonstrated additive mortality benefit from combining pentoxifylline with prednisolone, and routine combination is not recommended.
Option E: Option E is incorrect because active untreated infection is an absolute contraindication to steroids but does not make pentoxifylline an effective substitute, since it lacks proven mortality benefit in alcoholic hepatitis.
4. Before initiating prednisolone in a patient with severe alcoholic hepatitis, which of the following is an absolute contraindication that must be excluded?
A) A serum bilirubin above 10 mg/dL
B) A Maddrey discriminant function above 50
C) Uncontrolled active infection or sepsis
D) Concurrent thiamine supplementation
E) Documented alcohol abstinence for more than 7 days
ANSWER: C
Rationale:
Uncontrolled active infection or sepsis is an absolute contraindication to corticosteroids in severe alcoholic hepatitis, because steroid-induced immunosuppression in an already immune-dysregulated cirrhotic patient can produce lethal bacterial or fungal infection; mandatory pre-treatment screening includes blood and urine cultures, chest imaging, and diagnostic paracentesis if ascites is present.
Option A: Option A is incorrect because a high bilirubin reflects disease severity and is part of the criteria identifying steroid candidates, not a contraindication.
Option B: Option B is incorrect because a high discriminant function defines the severe disease for which steroids are indicated; it favors, rather than prohibits, treatment.
Option D: Option D is incorrect because thiamine supplementation is recommended supportive care to prevent Wernicke encephalopathy and is entirely compatible with steroid therapy.
Option E: Option E is incorrect because alcohol abstinence is the single most important determinant of long-term survival and supports, rather than contraindicates, treatment.
5. Resmetirom became the first drug specifically approved for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-severe fibrosis. What is its molecular mechanism of action?
A) Glucagon-like peptide-1 receptor agonism
B) Peroxisome proliferator-activated receptor-gamma agonism
C) Farnesoid X receptor agonism
D) Antioxidant scavenging of reactive oxygen species
Resmetirom is a selective thyroid hormone receptor-beta agonist; because receptor-beta is the predominant hepatic isoform, agonism increases hepatic fatty acid oxidation, reduces lipogenesis, and lowers low-density lipoprotein cholesterol without the cardiac and skeletal effects driven by receptor-alpha activation.
Option A: Option A is incorrect because glucagon-like peptide-1 receptor agonism describes semaglutide, not resmetirom.
Option B: Option B is incorrect because peroxisome proliferator-activated receptor-gamma agonism is the mechanism of pioglitazone.
Option C: Option C is incorrect because farnesoid X receptor agonism describes obeticholic acid, used in cholestatic disease rather than as a thyroid receptor agonist.
Option D: Option D is incorrect because antioxidant scavenging of reactive oxygen species describes vitamin E, not the receptor-mediated mechanism of resmetirom.
6. For a patient newly diagnosed with MASLD (metabolic dysfunction-associated steatotic liver disease), which intervention is the foundational and most evidence-based first step in management?
A) Initiating vitamin E at 800 international units daily
B) Caloric restriction and exercise to achieve 7 to 10 percent body weight loss
C) Starting resmetirom regardless of fibrosis stage
D) Beginning obeticholic acid to suppress bile acid synthesis
E) Initiating lactulose to reduce ammonia absorption
ANSWER: B
Rationale:
Lifestyle modification through caloric restriction and aerobic exercise to achieve 7 to 10 percent body weight loss is the foundational and most evidence-based intervention in MASLD and MASH, producing histological improvement in steatohepatitis and fibrosis regression when sustained.
Option A: Option A is incorrect because vitamin E is a pharmacological add-on with only borderline fibrosis evidence and is not the foundational step.
Option C: Option C is incorrect because resmetirom is approved specifically for fibrosis stages F2 to F3 and is not used indiscriminately; lifestyle change still precedes and accompanies it.
Option D: Option D is incorrect because obeticholic acid is a therapy for cholestatic disease, not a treatment for MASLD.
Option E: Option E is incorrect because lactulose treats hepatic encephalopathy and has no role in the management of steatotic liver disease.
7. A patient with primary biliary cholangitis (PBC: an autoimmune disease of the small intrahepatic bile ducts) is started on first-line therapy. Which agent is first-line, and what is its principal mechanism?
A) Ursodeoxycholic acid, which displaces toxic hydrophobic bile acids from the bile acid pool
B) Obeticholic acid, which blocks the farnesoid X receptor to increase bile acid synthesis
C) Bezafibrate, which antagonizes peroxisome proliferator-activated receptor-alpha
D) Cholestyramine, which dissolves intrahepatic bile duct strictures
E) Rifaximin, which sterilizes the biliary tree of urease-producing bacteria
ANSWER: A
Rationale:
Ursodeoxycholic acid is the established first-line treatment for primary biliary cholangitis; as a hydrophilic bile acid it competitively displaces toxic hydrophobic bile acids such as chenodeoxycholic and deoxycholic acid from the pool, reducing their cytotoxicity to cholangiocytes, with additional cytoprotective and immunomodulatory effects.
Option B: Option B is incorrect on two counts: obeticholic acid is second-line, and it is a farnesoid X receptor agonist that suppresses bile acid synthesis rather than a blocker that increases it.
Option C: Option C is incorrect because bezafibrate is a third-line agent and is an agonist, not an antagonist, of peroxisome proliferator-activated receptor-alpha.
Option D: Option D is incorrect because cholestyramine is a bile acid sequestrant used for pruritus and does not dissolve strictures.
Option E: Option E is incorrect because rifaximin is a gut-restricted antibiotic for hepatic encephalopathy and has no role in PBC or biliary sterilization.
8. A patient with primary biliary cholangitis has an inadequate biochemical response to ursodeoxycholic acid and is started on obeticholic acid (a farnesoid X receptor agonist). Which adverse effect is the principal dose-limiting toxicity of this agent?
A) Weight gain and fluid retention
B) Dose-related reduction in low-density lipoprotein cholesterol
C) Myopathy when combined with statins
D) Pruritus severe enough to require dose reduction or discontinuation
E) Bladder cancer with use beyond two years
ANSWER: D
Rationale:
Pruritus is the principal dose-limiting adverse effect of obeticholic acid, occurring in roughly 50 to 70 percent of patients and frequently severe enough to force dose reduction or discontinuation; obeticholic acid commonly worsens cholestatic itch.
Option A: Option A is incorrect because weight gain and fluid retention characterize pioglitazone, not obeticholic acid.
Option B: Option B is incorrect because a reduction in low-density lipoprotein cholesterol is a pharmacodynamic effect of resmetirom and is not the dose-limiting toxicity of obeticholic acid.
Option C: Option C is incorrect because statin-associated myopathy is a concern with fibrates such as bezafibrate, not the defining limitation of obeticholic acid.
Option E: Option E is incorrect because bladder cancer with prolonged use is a labeling concern for pioglitazone, not obeticholic acid.
9. Lactulose is the first-line agent for hepatic encephalopathy (HE: brain dysfunction from liver insufficiency and portosystemic shunting). Which mechanism best explains how it lowers blood ammonia?
A) It is absorbed systemically and directly inhibits hepatic urea cycle enzymes
B) It sterilizes the colon by killing urease-producing bacteria
C) Colonic acidification converts ammonia to ammonium, which is trapped in the lumen for fecal excretion
D) It chelates ammonia in the bloodstream and promotes renal excretion
E) It blocks ammonia transport across the blood-brain barrier
ANSWER: C
Rationale:
Colonic bacteria hydrolyze lactulose to organic acids that acidify the lumen to a pH near 5 to 5.5, converting ammonia to membrane-impermeant ammonium that is trapped in the colon and excreted in stool; the osmotic cathartic effect further reduces transit time and ammonia generation.
Option A: Option A is incorrect because lactulose is a non-absorbable disaccharide that acts in the gut lumen and does not enter the circulation to inhibit hepatic enzymes.
Option B: Option B is incorrect because killing urease-producing bacteria describes rifaximin; lactulose works by acidification and catharsis, not antibacterial sterilization.
Option D: Option D is incorrect because lactulose does not chelate circulating ammonia or act through the kidney.
Option E: Option E is incorrect because lactulose does not block blood-brain barrier ammonia transport; it lowers the systemic ammonia load at its gut source.
10. Rifaximin is added to lactulose in hepatic encephalopathy. Which property best explains its therapeutic profile and favorable safety in this setting?
A) High systemic absorption allowing it to neutralize ammonia in the blood
B) Selective enhancement of colonic ammonium absorption
C) Direct stimulation of hepatic ammonia metabolism
D) Broad disruption of the entire gut microbiome at standard doses
E) Minimal systemic bioavailability, concentrating antibacterial activity within the gut lumen
ANSWER: E
Rationale:
Rifaximin has systemic bioavailability under 0.4 percent, so its broad-spectrum antibacterial activity is concentrated within the intestinal lumen, where it suppresses urease-producing ammonia-generating bacteria; this gut-restricted profile underlies its low resistance-selection potential and absence of significant drug interactions.
Option A: Option A is incorrect because rifaximin is essentially non-absorbed and does not act in the bloodstream.
Option B: Option B is incorrect because rifaximin reduces ammonia generation by suppressing bacteria, not by enhancing ammonium absorption, which would worsen encephalopathy.
Option C: Option C is incorrect because rifaximin acts in the gut and does not directly stimulate hepatic ammonia metabolism.
Option D: Option D is incorrect because at standard doses rifaximin reduces ammonia-generating species without substantially altering overall microbiome composition.
11. Pioglitazone has demonstrated histological improvement in MASH and may be considered, particularly with concurrent type 2 diabetes. Which condition is an absolute contraindication to its use?
A) Compensated cirrhosis without ascites
B) Heart failure
C) Hyperlipidemia
D) Stage F2 hepatic fibrosis
E) Prediabetes
ANSWER: B
Rationale:
Heart failure is an absolute contraindication to pioglitazone, because its peroxisome proliferator-activated receptor-gamma agonism promotes sodium retention and fluid redistribution that can precipitate or worsen decompensation.
Option A: Option A is incorrect because compensated cirrhosis without ascites is not in itself an absolute contraindication to pioglitazone.
Option C: Option C is incorrect because hyperlipidemia is not a contraindication; it is a metabolic comorbidity often present in these patients.
Option D: Option D is incorrect because stage F2 fibrosis describes the disease being treated, not a contraindication.
Option E: Option E is incorrect because prediabetes actually favors pioglitazone use, since insulin sensitization provides additional metabolic benefit.
12. Which statement most accurately characterizes pharmacological management of primary sclerosing cholangitis (PSC: fibro-inflammatory stricturing of intrahepatic and extrahepatic bile ducts)?
A) No pharmacological agent has been proven to halt fibrosis or improve transplant-free survival
B) High-dose ursodeoxycholic acid at 28 to 30 mg/kg/day is the proven standard of care
C) Obeticholic acid reliably reverses biliary strictures in PSC
D) Bezafibrate is FDA-approved as disease-modifying therapy for PSC
E) Rifaximin halts progression of biliary fibrosis in PSC
ANSWER: A
Rationale:
Primary sclerosing cholangitis has no pharmacological agent proven to halt or reverse biliary fibrosis or improve transplant-free survival, so management centers on surveillance for cholangiocarcinoma and colorectal cancer, endoscopic treatment of dominant strictures, and timely transplant evaluation.
Option B: Option B is incorrect because high-dose ursodeoxycholic acid at 28 to 30 mg/kg/day increased adverse events in a randomized trial and is actively contraindicated, not standard care.
Option C: Option C is incorrect because obeticholic acid is a therapy for primary biliary cholangitis and does not reverse strictures in PSC.
Option D: Option D is incorrect because bezafibrate is not FDA-approved for PSC and has no proven disease-modifying role in it.
Option E: Option E is incorrect because rifaximin treats hepatic encephalopathy and does not affect biliary fibrosis.
13. When titrating lactulose for hepatic encephalopathy, what is the appropriate dosing endpoint, and why does overshooting it cause harm?
A) Titrate to a single firm stool daily, because more frequent stooling fails to lower ammonia
B) Titrate to the maximum tolerated dose, because more stools always improve outcomes
C) Titrate until diarrhea occurs, because only liquid stool clears ammonia effectively
D) Titrate to two to three soft stools daily, because over-purging causes dehydration and hypernatremia that themselves precipitate encephalopathy
E) Titrate to no stooling, because retained lactulose maximizes colonic acidification
ANSWER: D
Rationale:
Lactulose is titrated to two to three soft stools per day; over-purging beyond four stools daily produces dehydration and hypernatremia, which are themselves precipitants of hepatic encephalopathy and therefore counterproductive.
Option A: Option A is incorrect because a single firm stool indicates inadequate catharsis and acidification, and frequent soft stooling is precisely the therapeutic goal.
Option B: Option B is incorrect because more stooling is not uniformly beneficial; excessive purging is harmful.
Option C: Option C is incorrect because driving the patient to frank diarrhea risks the same fluid and electrolyte disturbances that precipitate encephalopathy.
Option E: Option E is incorrect because withholding stooling defeats the osmotic and acidifying mechanism by which lactulose works.
14. A patient with primary biliary cholangitis has an inadequate response to ursodeoxycholic acid and cannot tolerate obeticholic acid because of severe pruritus. Which third-line option is attractive specifically because it tends to improve itch?
A) Higher-dose obeticholic acid
B) Naltrexone monotherapy as a disease-modifying agent
C) Bezafibrate, a peroxisome proliferator-activated receptor-alpha agonist
D) High-dose ursodeoxycholic acid at 30 mg/kg/day
E) Cholestyramine as definitive biochemical therapy
ANSWER: C
Rationale:
Bezafibrate, a peroxisome proliferator-activated receptor-alpha agonist, is a third-line option for primary biliary cholangitis after inadequate response to or intolerance of ursodeoxycholic acid plus obeticholic acid; it produces biochemical response in a meaningful minority of patients and paradoxically improves pruritus, making it attractive for the obeticholic-intolerant patient with severe itch.
Option A: Option A is incorrect because increasing obeticholic acid would worsen the very pruritus that limited it.
Option B: Option B is incorrect because naltrexone is a symptomatic antipruritic acting through central opioid antagonism, not a disease-modifying biochemical therapy.
Option D: Option D is incorrect because high-dose ursodeoxycholic acid is contraindicated in cholestatic disease management as framed here and is not a PBC third-line strategy.
Option E: Option E is incorrect because cholestyramine is a first-line antipruritic sequestrant, not a definitive therapy that normalizes the cholestatic biochemistry.
15. A patient with cholestatic pruritus from primary biliary cholangitis needs symptom control. According to the standard stepwise approach, which agent is first-line, and by what mechanism does it relieve itch?
A) Rifampicin, by central opioid antagonism
B) Naltrexone, by upregulating bile acid detoxification
C) Sertraline, by sequestering luminal bile acids
D) Rifampicin, by chelating ammonia in the colon
E) Cholestyramine, by sequestering bile acids in the gut lumen
ANSWER: E
Rationale:
Cholestyramine is the first-line agent for cholestatic pruritus; as a bile acid sequestrant it binds bile acids in the intestinal lumen and interrupts their enterohepatic recycling, lowering the accumulated bile acids that drive itch.
Option A: Option A is incorrect because rifampicin is a second-line antipruritic that works by pregnane X receptor-mediated upregulation of bile acid detoxification, not by opioid antagonism.
Option B: Option B is incorrect because naltrexone is a third-line agent acting through central opioid antagonism, not through bile acid detoxification.
Option C: Option C is incorrect because sertraline is a fourth-line option and does not sequester luminal bile acids.
Option D: Option D is incorrect because rifampicin does not chelate colonic ammonia; that conflates it with agents used in hepatic encephalopathy.
16. A patient presents with severe alcoholic hepatitis. Applying the scoring tools covered earlier, which sequence correctly orders their use in the treatment decision?
A) Use the Maddrey discriminant function to select patients for steroids, then use the day-7 Lille score to decide whether to continue or stop them
B) Use the Lille score at admission to select patients for steroids, then use the Maddrey function at day 7 to decide continuation
C) Use the Maddrey function both to select patients and to define non-response at day 7
D) Use the Lille score both to select patients and to confirm severity at admission
E) Use neither score; treat all patients with alcoholic hepatitis with steroids for 28 days
ANSWER: A
Rationale:
The Maddrey discriminant function is the entry criterion, identifying patients with severe disease who are candidates for corticosteroids, and the Lille score at day 7 then determines whether the steroid course should continue or stop based on early response; this matches the roles established earlier in this set.
Option B: Option B inverts the two tools: the Lille score is a day-7 response measure, not an admission selection tool, and the Maddrey function is a baseline severity score, not a day-7 measure.
Option C: Option C is incorrect because the Maddrey function does not define day-7 non-response; that is the role of the Lille score.
Option D: Option D is incorrect because the Lille score is not an admission severity tool; severity selection is the Maddrey function's role.
Option E: Option E is incorrect because treating all patients indiscriminately ignores both contraindication screening and the Lille-based stopping rule, exposing non-responders to needless immunosuppression.
17. A cirrhotic patient has just recovered from a first hospitalization for overt hepatic encephalopathy while taking lactulose. Applying the agents discussed earlier, what is the appropriate strategy for secondary prophylaxis?
A) Stop lactulose and switch entirely to rifaximin monotherapy
B) Continue lactulose alone, because adding rifaximin offers no benefit over lactulose
C) Add rifaximin to ongoing lactulose, because the combination is superior to either agent alone for preventing recurrence
D) Replace lactulose with a systemic antibiotic such as neomycin for broader coverage
E) Discontinue both agents once the acute episode has resolved
ANSWER: C
Rationale:
Rifaximin is indicated as an add-on to ongoing lactulose for secondary prophylaxis after an episode of overt encephalopathy, and the combination is superior to either agent alone for preventing recurrence; this applies the gut-restricted mechanism of rifaximin and the cathartic-acidifying mechanism of lactulose established earlier.
Option A: Option A is incorrect because rifaximin is add-on therapy, not a monotherapy replacement for lactulose.
Option B: Option B is incorrect because adding rifaximin to lactulose reduced breakthrough episodes and hospitalizations, so it does offer benefit.
Option D: Option D is incorrect because a systemic antibiotic introduces systemic toxicity and resistance concerns that the non-absorbed rifaximin avoids, and replacing lactulose removes its independent benefit.
Option E: Option E is incorrect because stopping therapy after an episode abandons secondary prophylaxis and invites recurrence.
18. A cirrhotic patient on stable lactulose presents with new confusion and asterixis. A rectal examination reveals melena. Applying the precipitant framework discussed earlier, what is the single most impactful initial intervention?
A) Doubling the maintenance lactulose dose and observing for 48 hours
B) Identifying and correcting the precipitant by managing the gastrointestinal bleed, since luminal blood is a large nitrogen load for ammonia generation
C) Starting an empiric benzodiazepine for agitation
D) Immediately listing the patient for liver transplantation
E) Adding branched-chain amino acid supplementation as primary therapy
ANSWER: B
Rationale:
Precipitant identification and correction is the single most impactful intervention in acute overt encephalopathy and is often more effective than escalating drug therapy alone; here the gastrointestinal bleed must be managed because luminal blood is a large nitrogen load that colonic bacteria convert to ammonia.
Option A: Option A is incorrect because simply increasing lactulose without addressing the bleed leaves the driving precipitant uncorrected.
Option C: Option C is incorrect because benzodiazepines are themselves potent precipitants of encephalopathy and would worsen the patient.
Option D: Option D is incorrect because transplant listing is not the immediate step for a reversible precipitated episode.
Option E: Option E is incorrect because branched-chain amino acids are an adjunctive, not primary, therapy and do not address the active bleed.
19. Three nuclear-receptor-targeted hepatic drugs were discussed: pioglitazone, resmetirom, and obeticholic acid. Which pairing of drug to receptor target is entirely correct?
A) Pioglitazone targets the thyroid hormone receptor-beta; resmetirom targets the farnesoid X receptor
B) Resmetirom targets peroxisome proliferator-activated receptor-gamma; obeticholic acid targets the thyroid hormone receptor-beta
C) Obeticholic acid targets peroxisome proliferator-activated receptor-gamma; pioglitazone targets the farnesoid X receptor
D) Resmetirom targets the farnesoid X receptor; pioglitazone targets the thyroid hormone receptor-beta
E) Pioglitazone targets peroxisome proliferator-activated receptor-gamma; resmetirom targets the thyroid hormone receptor-beta; obeticholic acid targets the farnesoid X receptor
ANSWER: E
Rationale:
Pioglitazone is a peroxisome proliferator-activated receptor-gamma agonist, resmetirom is a selective thyroid hormone receptor-beta agonist, and obeticholic acid is a farnesoid X receptor agonist; only this option matches all three correctly.
Option A: Option A is incorrect because it assigns the thyroid receptor to pioglitazone and the farnesoid X receptor to resmetirom, swapping their true targets.
Option B: Option B is incorrect because resmetirom is not a peroxisome proliferator-activated receptor-gamma agonist and obeticholic acid is not a thyroid receptor agonist.
Option C: Option C is incorrect because obeticholic acid is not a peroxisome proliferator-activated receptor-gamma agonist and pioglitazone is not a farnesoid X receptor agonist.
Option D: Option D is incorrect because resmetirom is not a farnesoid X receptor agonist and pioglitazone is not a thyroid receptor agonist.
20. A patient with MASH and stage F3 fibrosis is started on resmetirom. The patient is also taking a medication that is a strong inducer of CYP3A4 (cytochrome P450 3A4, a major drug-metabolizing enzyme). Why is this combination problematic?
A) Resmetirom inhibits CYP3A4, so the other drug will accumulate to toxic levels
B) Resmetirom is approved for cirrhosis, so enzyme interactions are irrelevant
C) The combination raises resmetirom levels and mandates a dose increase
D) Resmetirom is a CYP3A4 substrate, so a strong inducer can lower its levels and reduce efficacy
Resmetirom is a substrate of CYP3A4, so co-administration with a strong CYP3A4 inducer such as rifampin or phenytoin accelerates its metabolism, lowering drug exposure and reducing efficacy; strong inducers should therefore be avoided.
Option A: Option A is incorrect because the interaction arises from resmetirom being a substrate of the enzyme, not an inhibitor of it.
Option B: Option B is incorrect because resmetirom is not approved for cirrhosis and should be avoided in Child-Pugh B or C disease, so the premise is wrong.
Option C: Option C is incorrect because an inducer lowers, not raises, resmetirom levels, and the correct response is to avoid the inducer rather than increase the dose.
Option E: Option E is incorrect because the problem is pharmacokinetic loss of resmetirom exposure, not an inducer-driven rise in low-density lipoprotein cholesterol.
21. A cirrhotic patient on diuretics develops hypokalemia and a metabolic alkalosis, and then becomes encephalopathic. Applying the principles covered earlier, why does this electrolyte and acid-base disturbance precipitate hepatic encephalopathy?
A) Alkalosis shifts the ammonia-ammonium equilibrium toward un-ionized, diffusible ammonia, which more readily crosses the blood-brain barrier
B) Hypokalemia directly destroys hepatocytes, abolishing ammonia metabolism
C) Alkalosis increases lactulose absorption, reversing its benefit
D) Hypokalemia sterilizes the gut, eliminating beneficial bacteria
E) Alkalosis converts ammonia to membrane-impermeant ammonium, trapping it in the brain
ANSWER: A
Rationale:
An alkaline pH shifts the equilibrium between ammonium and ammonia toward un-ionized ammonia, which is lipid-soluble and diffusible and therefore crosses the blood-brain barrier more readily; hypokalemia and alkalosis (commonly diuretic-induced) are recognized precipitants of encephalopathy through this mechanism.
Option B: Option B is incorrect because hypokalemia does not directly destroy hepatocytes; its effect is on the ammonia-ammonium equilibrium and renal ammonia handling, not cytolysis.
Option C: Option C is incorrect because alkalosis does not increase absorption of the non-absorbable disaccharide lactulose.
Option D: Option D is incorrect because hypokalemia does not sterilize the gut.
Option E: Option E inverts the chemistry: alkalosis favors diffusible ammonia, not impermeant ammonium, and ammonium is not trapped in the brain by this shift.
22. A patient with severe alcoholic hepatitis on prednisolone has a day-7 Lille score of 0.10. Applying the response categories established earlier, how is this classified, and what should be done?
A) Non-response; discontinue prednisolone immediately
B) Partial response; let clinical judgment govern continuation
C) Complete response; continue prednisolone for the full 28-day course
D) Non-response; extend prednisolone beyond 28 days
E) Partial response; switch to intravenous methylprednisolone
ANSWER: C
Rationale:
A Lille score below 0.16 defines complete response, with a 6-month mortality under 15 percent, and indicates that prednisolone should be continued for the full 28-day course; a value of 0.10 falls clearly in this category.
Option A: Option A is incorrect because non-response is defined by a Lille score of 0.45 or greater, the opposite end of the scale from 0.10.
Option B: Option B is incorrect because partial response corresponds to scores between 0.16 and 0.45, not below 0.16.
Option D: Option D is incorrect because a score of 0.10 is a complete response, not non-response, and therapy is not extended beyond 28 days.
Option E: Option E is incorrect because the score reflects a complete response, and switching to an intravenous formulation is not indicated; oral prednisolone is the preferred formulation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.